Natera, Inc. announced successful topline results from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study in colorectal cancer. The readout, involving approximately 1,000 patients, demonstrated a significant clinical benefit for Signatera-positive patients.
Patients treated with both chemotherapy and celecoxib, guided by Signatera, showed a 40% improvement in overall survival compared to those receiving chemotherapy alone. This marks an unprecedented moment in personalized medicine for colorectal cancer patients.
This first-of-its-kind study evaluated Signatera’s ability to predict a benefit from an escalation in adjuvant treatment. The results offer compelling evidence to address an unmet need in adjuvant colorectal cancer treatment, where new drug approvals have been scarce for over 20 years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.